1. Yong has added a comment to the discussion board:
https://confluence.ihtsdotools.org/display/USRG/Additional+Attributes+for+National+Drug+Extensions
This includes a proposed new MRCM for 30465011000036106 |Has container type (attribute)|. Yong has raised questions regarding the domain, range (especially with respect to specific physical object values), and cardinality (also consider multi-container products, subpacks, and the implications for classification).

2. The attributes list from Canada is also available on the discussion board. Additional relevant content can be found on this page:
https://confluence.ihtsdotools.org/display/USRG/Medication+MRCM+Extensions

What are members requirements in the area of additional attributes?

Request for feedback on Patches strength representation

Group feedback on applying ongoing patch strength changes to Vaginal Rings

• Less Granular Clinical Drug
• Elemental Substances (Matt, AUS)
• Substances Co-ordination (MF/2025 Priority topic)
  • Step 1: Substances in multiple extensions Batch promotions complete, SI review and authoring underway
  • Step 2: Substances in one extension
  • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)
• Medication Stopped v Medication Discontinued (Karen, SI)
• Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work + ES)
• Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 
• Increase range of has active ingredient to include microorganisms and natural products (Guillermo)
• Link between Substances and the organism they come from (Cat dander protein → Cat organism) see PCP-68
• Units of Measure - proposal for rationalisation of concepts (Emma, UK)

Done or in progress:

• Hydration Subsumption 'Option 3' proposed by DEUSG for communication/consultation with MAG and EAG
• Group Input on Patch Strength Representation Briefing note now being implemented
• Dose Form Intended Site v Route of Administration (BEL) Pending implementation use-cases associated with intended site
• Drug extension MRCM attributes (CA, AUS) SI facilitating links with CA and AUS for cross-promotion, next steps: other countries to be invited to add to catalogue
• Value range of a |Has container type| attribute (Linda, CA)
• Routes of Administration - Implementation Considerations (Mia, NZ)